The recently unveiled conjugate DS3610a is to start phase 1.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Tolerability could decide first-line therapy in EGFRm disease.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
